Article Summary
洪甲1 姚丽2 张佳瑞2 任拼2 王姝妹2 兰淼2 李艳红1△ 张伟2△.miR-450a-5p 在浆液性卵巢癌中的表达及临床意义*[J].现代生物医学进展英文版,2014,14(17):3240-3243.
miR-450a-5p 在浆液性卵巢癌中的表达及临床意义*
The Expression and Clinical Significance of miR-450a-5pin Serous Ovarian Cancer*
  
DOI:
中文关键词: 浆液性卵巢癌  输卵管伞端组织  miR-450a-5p  实时荧光定量PCR
英文关键词: Serous ovarian cancer  Fimbria of fallopian tube  miR-450a-5p  Real-time fluorescent quantitative PCR
基金项目:教育部留学回国人员科研启动基金(HG3310);陕西省科技攻关课题(2007K09-09);
Author NameAffiliation
HONG Jia, YAO Li, ZHANG Jia-rui,REN Pin, WANG Shu-mei, LAN Miao, LI Yan-hong, ZHANG Wei 1第四军医大学唐都医院妇产科陕西西安7100382 第四军医大学唐都医院病理科陕西西安710038 
Hits: 690
Download times: 888
中文摘要:
      摘要目的:检测miR-450a-5p 在浆液性卵巢癌中的表达情况,并分析miR-450a-5p的表达与浆液性卵巢癌临床病理特征之间的 关系,探讨其在浆液性卵巢癌发生、发展中的意义。方法:采用实时荧光定量PCR 技术,检测101 例浆液性卵巢癌组织及对照50 例正常输卵管伞端组织中miR-450a-5p 的表达情况,并分析miR-450a-5p表达水平与临床病理特征之间的关系。实验数据采用统 计学软件进行分析。结果:miR-450a-5p 在浆液性卵巢癌组织中的表达量显著低于正常输卵管组织对照组(P<0.01)。miR-450a-5p 的表达水平与浆液性卵巢癌临床病理特征之间差异均无统计学意义(P> 0.05)。结论:miR-450a-5p 可能作为抑癌基因,在卵巢癌 的发生、发展中发挥重要作用,进一步的研究有望为浆液性卵巢癌的早期诊断及个体化治疗提供新的理论依据。
英文摘要:
      ABSTRACT Objective:To investigate the expression of miR-450a-5p in serous ovarian cancer, and analyze the correlation of its expression with clinicpathological features and investigate the significance of miR-450a-5p in ovarian cancer carcinogenesis and development.Methods: Quantitative real-time PCR was used to assess the expression of miR-450a-5p in 101 serous ovarian cancer tissues and 50 normal fimbria of fallopian tube tissues, and the results were assessed with statistic analysis. Results:The expression of miR-450a-5p in serous ovarian cancer tissues down-regulated significantly than that in normal fimbria of fallopian tube tissues (P< 0.01). There was no significant difference for expression of miR-450a-5p with clinicopathological features in serous ovarian cancer (P> 0.05).Conclusion: miR-450a-5p may play an important role as a tumor-suppressor in the occurrence and development of serous ovarian cancer and may provide new basic theories for the earlier diagnosis and target treatment of serous ovarian cancer.
View Full Text   View/Add Comment  Download reader
Close